Related Experiment Video
Updated: May 28, 2026
08:48
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and
Diana-Maria Mateescu1, Dragos-Mihai Gavrilescu2, Florin Eugen Constantinescu3
1Department of General Medicine, Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
Pharmaceutics
|May 27, 2026
Summary
Body protection compound 157 (BPC-157) shows promise but lacks pharmaceutical development. Key barriers include uncharacterized formulations and pharmacokinetics, hindering clinical advancement.
Area of Science:
- Peptide drug development
- Biopharmaceutical sciences
- Translational medicine
Background:
- BPC-157, a synthetic pentadecapeptide, demonstrates cytoprotective and regenerative properties in preclinical studies.
- Despite extensive research, BPC-157 lacks approved formulations, validated dosing, and completed clinical trials.
- This review focuses on the biopharmaceutical and drug development aspects of BPC-157.
Purpose of the Study:
- To critically evaluate BPC-157 from a biopharmaceutical and drug development perspective.
- To examine its physicochemical properties, formulation challenges, and pharmacokinetic-pharmacodynamic disconnect.
- To identify regulatory and translational barriers to clinical advancement.
Main Methods:
- A narrative literature review was conducted using PubMed/MEDLINE, Embase, and Cochrane Library.
- Searches included terms related to BPC-157, pharmacokinetics, formulation, and regulatory status.
- Patent and regulatory databases were searched, supplemented by citation tracking.
Main Results:
- BPC-157 exhibits stability and activity across multiple administration routes but has an undercharacterized human pharmacokinetic profile.
- Preclinical studies show a plasma half-life under 30 minutes, contrasting with prolonged biological effects.
- No pharmaceutical-grade formulations exist, and clinical data are limited to small, uncontrolled pilot studies.
Conclusions:
- BPC-157 possesses biological activity but is pharmaceutically underdeveloped.
- The primary barrier to clinical translation is the lack of fundamental pharmaceutical science, including characterized formulations and validated pharmacokinetics.
- Addressing these biopharmaceutical gaps is essential for future clinical programs.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...